GT Biopharma, Inc. (GTBP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US36254L3087
GT Biopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -12.42 m USD |
| EBIT | -28.23 m USD |
| Net income | -28.35 m USD |
| Diluted EPS – continuing operations | -6.68 USD |
Full history since 1983, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
More stocks
- Adaptimmune Therapeutics PLC (ADAPY)
- iQSTEL Inc (IQST)
- MultiSensor AI Holdings, Inc. (MSAI)
- Monroe Federal Bancorp, Inc. (MFBI)
- AMERICAS CARMART INC (CRMT)
- System1, Inc. (SST)
- Tempest Therapeutics, Inc. (TPST)
- Bodhi Tree Biotechnology Inc (BDTB)
- CFN Enterprises Inc. (CNFN)
- XERIANT, INC. (XERI)
- Bridgeline Digital, Inc. (BLIN)
- Curanex Pharmaceuticals Inc (CURX)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.